October 24, 2001

Not Assigned

Title:

P.O. Box 2327

under 37 CFR 1.97(i):


(Filed after payment of issue fee)

Filed:

Applicants:

Response of Dendritic Cells to a Diverse Set of Pathogens

Examiner:



Arlington, VA 22202 Sir: This Information Disclosure Statement is submitted: under 37 CFR 1.129(a), or (First/Second submission after Final Rejection) under 37 CFR 1.97(b), or [X] (Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination). under 37 CFR 1.97(c) together with either: a Statement under 37 CFR 1.97(e), as checked below, or a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first) under 37 CFR 1.97(d) together with: [] a Statement under 37 CFR 1.97(e), as checked below, and [] a \$180.00 fee under 37 CFR 1.17(p), or (Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

Staten	<u>ient Und</u>	<u>er 37 CFR 1.97(e)</u>						
[]	Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or							
[]	knowle	o item of information contained in this Information Disclosure Statement was cited in a immunication from a foreign patent office in a counterpart foreign application, and, to the lowledge of the undersigned, after making reasonable inquiry, no item of information contained the information disclosure statement was known to any individual designated in 37 CFR 56(c) more than three months prior to the filing of this Information Disclosure Statement.						
<u>Staten</u>	nent Unc	(Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000						
[]	commit was no	em of information contained in the Information Disclosure Statement was cited in a unication from a foreign patent office in a counterpart application and this communication t received by any individual designated in § 1.56(c) more than thirty days prior to the of the Information Disclosure Statement.						
[X]	Enclosed herewith is form PTO-1449:							
	[X]	Copies of the cited references (AR-AR3) are enclosed.						
	[]	Copies of cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earliapplication contains copies of the cited references.]						
	[]	The listed references were cited in the enclosed International Search Report in a counterpart foreign application.						
	[]	The "concise explanation" requirement (non-English references) for reference(s) [under 37 CFR 1.98(a)(3) is satisfied by:						
		[] the explanation provided on the attached sheet.						
		[] the explanation provided in the Specification.						
		[] submission of the enclosed International Search Report.						
		submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.						
		[] the enclosed English language abstract.						

[]	Applic	cant requests that the following r	on-published pending applic	cations be considered:			
Examiner's Initials	s						
	-	U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []			
	-	U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []			
	-	U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []			
		Examiner	Date	-			
	[]	A copy of each above-cited app	plication, including the curre	nt claims, is enclosed.			
	[]	A copy of each above-cited app those entered in prior application 35 U.S.C. 120 is claimed.	plication, including the curre on, U.S. Application No. [nt claims, is enclosed, except], to which priority under			
The E	xamine nces we	r is requested to return a copy of re considered with the next offic	the above list of pending ap e communication.	plications indicating which			
It is re	equested	I that the information disclosed h	erein be made of record in the	his application.			
Metho	od of pa	yment:					
[]		ck for the fee noted above is encorpanying Reply. A copy of this S		cluded in the check with the			
[]		lease charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is nclosed.					
[X]	Please	charge any deficiency in fees ar	nd credit any overpayment to	Deposit Account 08-0380.			
		F	Respectfully submitted,				
		F	HAMILTON, BROOK, SMI	TH & REYNOLDS, P.C.			
		F	Lisa M. Treannie Registration No.: 41,368 Telephone: (978) 341-0036 Facsimile: (978) 341-0136	<u> </u>			

Concord, MA 01742-9133 Dated: 8/9/07

PTO 1449 REPRODUCED				ATTORNEY DOCKET NO. 2825.2019-001	APPLICATION 10/085,98				
	INFORMATION DISCLOSURE CITATION IN AN APPLICATION			APPLICANTS Nir Hacohen, et al.	1-,		مَا اللهِ مِنْ اللهُ عِنْ اللهُ ع		
		May 28, 2002		FILING DATF	GROUP	AUG	5 1 6 2002 H		
	(Use	e several sheets if nece		October 24, 2001	1645	E V			
DVAM.	1	T	U.S.	PATENT DOCUMENTS		1	MOEMARY		
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME RECE	1	SUB- LASS	FILING DATE IF APPROPRIATE		
	AA			/NJG 3	2 y 1602				
			FOREIG	N PATENT DOCUMENTS		,			
		DOCUMENT NUMBER	DATE	COUNTRY EUH CENT	CLASS CI	UB- LASS	TRANSLATION YES NO		
	AL								
		OTHER DOCUMENTS	(Including Au	thor, Title, Date, Pertinent	Pages, Etc.	.)			
	AR 🗸	in Natural and A	Ashman, R. and Papadimitriou, J., "Production and Function of Cytokines in Natural and Acquired Immunity to Candida albicans Infection," Microbiol. Rev., 59(4):646-672 (1995).						
	AS ✓	Banchereau, J. a Immunity," Natur	and Steinmar re, 392:245	n, R., "Dendritic Cells -252 (1998).	and the (Contr	ol of		
	AT V	Banchereau, J. et al., "Immunobiology of Dendritic Cells," Annu. Rev. Immunol., 18:767-811 (2000).							
	AU	Bhardwaj, N. et al., "Influenza Virus-infected Dendritic Cells Stimulate Strong Proliferative and Cytolytic Responses from Human CD8+ T Cells," J. Clin. Invest., 94:797-807 (1994).							
	AV /			ve Suppression of IL-12 nol., 164:3009-3017 (20)		on by			
	AW	Cella, M. et al., "Maturation, Activation, and Protection of Dendritic Cells Induced by Double-stranded RNA," J. Exp. Med., 189(5):821-829 (1999).							
	AX	Dietz, A. et al., "Maturation of Human Monocyte-Derived Dendritic Cells Studied by Microarray Hybridization," Biochem. Biophys. Res. Commun., 275:731-738 (2000).							
	AY J	d'Ostiani, C. et al., "Dendritic Cells Discriminate Between Yeasts and Hyphae of the Fungus Candida albicans: Implications for Initiation of T Helper Cell Immunity In Vitro and In Vivo," J. Exp. Med., 191(10):1661-1673 (2000).							
		Hashimoto, S. et al., "Identification of Genes Specifically Expressed in Human Activated and Mature Dendritic Cells Through Serial Analysis of Gene Expression," Blood, 96(6):2206-2214 (2000).							
	AR2	Hemmi, H. et al., "A Toll-like Receptor Recognizes Bacterial DNA," Nature, 408:740-745 (2000).							
	AS2	Hwu, P. et al., "Indoleamine 2,3-Dioxygenase Production by Human Dendritic Cells Results in the Inhibition of T Cell Proliferation," J. Immunol., 164:3596-3599 (2000).							
EXAMINER				DATE CONSIDERED					

PTO 1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION				ATTORNEY DOCKET NO. 2825.2019-001	APPLICATION NO. 10/085,982			
				APPLICANTS Nir Hacohen, et al.		Alle	1 6 2002	7C98
May 28, 2002 (Use several sheets if necessary)				FILING DATE October 24, 2001	GROUP 1645	THE STATE OF THE S		S S S S S S S S S S S S S S S S S S S
			U.S.	PATENT DOCUMENTS				
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB - CLASS	FILING IE APPROP	7
	_		FOREIG	N PATENT DOCUMENTS			_	
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSL YES	ATION ON
		OTHER DOCUMENTS	(Including Au	thor, Title, Date, Pertinent	t Pages,	Etc.)		
	AT2/							
	AU2	,						
	AV2	O'Reilly, L. and Strasser, A., "Apoptosis and Autoimmune Disease," Inflamm. Res., 48:5-21(1999).						
	AW2	Rescigno, M. et al., "Bacteria-induced Neo-biosynthesis, Stabilization, and Surface Expression of Functional Class I Molecules in Mouse Dendritic Cells," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 95:5229-5234 (1998).						
	AX2	Rissoan, M. et al., "Reciprocal Control of T Helper Cell and Dendritic Cell Differentiation," Science, 283:1183-1186 (1999).						
	AY2	Tomasec, P. et al., "Surface Expression of HLA-E, an Inhibitor of Natural Killer Cells, Enhanced by Human Cytomegalovirus gpUL40," Science, 287:1031-1033 (2000).						
	AZ	von Andrian, U. and Mackay, C., "T-Cell Function and Migration: Two Sides of the Same Coin," New Engl. J. Med., 343(14):1020-1034 (2000).						
	AR3	Wenger, R., "Mammalian Oxygen Sensing, Signalling and Gene Regulation," J. Exp. Biol., 203:1253-1263 (2000).						
EXAMINER DATE CONSIDERED								

RECEIVED

AUG 2 0 2002

TECH CENTER 1600/2900